Value Investor
Start free

PTC Therapeutics

PTCT on Nasdaq. PTC Therapeutics sells medicines for rare diseases to patients and doctors. Market value $5.3bn.

Watch this stockFree. We tell you when something changes.

Price checks use the past 12 months to June 2026. Quality checks use five annual reports, the latest for the year to December 2025.

We can't read total debt from the filing, so debt is left out.

Should I look at this?

Not a fit for our list right now

Why it could be worth it

What to watch out for

See Health care stocks that passed both tests

This is not advice. Check the numbers below.

Compare with another stock

Cash yield
past 12 months to June 2026
-0.7%low

For every $100 of what the whole company costs, it produced $-0.75 of spare cash in the past 12 months. A savings account pays about $4.

Price to profit
past 12 months to June 2026
38.7×full

You pay 38.7 years of operating profit for the business. The average large US company costs around 18.

Return on capital
five annual reports to December 2025
n/a

The filings do not give us enough to work this out.

Quality score: 34 of 100. Price score: 0 of 100. Our list needs 70 on quality and 60 on price.

$63.70 a share, 4% above its 1-year low

Over the past year the price has ranged from $61.23 to $90.87.

Pays no dividend

Prices from Tuesday’s close (6 October).

Five years of cash, in billions

-0.3
-0.4
-0.2
-0.1
0.7
-0.0
2021202220232024202512 monthsto Jun '26

Spare cash swings from quarter to quarter here: a shortfall of $40 million in the past 12 months, $702 million in the year to December 2025.

Revenue
$539m$699m$938m$807m$1.7bn
Operating margin
-69.5%-64.0%-46.9%-37.5%50.1%
Debt to equity
316.05n/an/an/an/a
Shares outstanding
0.07bn0.08bn0.08bn0.08bn0.08bn

Health checks

  • Free cash flow positive1 of 5 years
  • Accounting looks honest (Beneish)Not enough data
  • Financial strength (Piotroski)5 of 7 checks we could run
  • Profit backed by cash (accruals)Yes
  • DebtUnknown
  • Revenue growth, five yearsStrong, 35.4% a year
  • Buying back its own sharesNo, 16% more shares since 2021

The quarter to June 2026

How the business did, compared with the same quarter a year earlier.

  • Sales: $361 million last quarter, up 102% on a year ago.
  • Profit: $83 million, after a loss of $65 million a year ago.
  • It keeps 12 cents of each $1 of sales as operating profit, down from 41 cents a year earlier.
  • Over the past 12 months it spent $40 million more cash than it brought in. A year earlier it had $698 million spare.
  • 18% more shares than a year ago. Each share owns a bit less of the company.
  • It has $453 million more cash than debt, down from $712 million a year ago.
  • Sales grew on a year ago in 2 of the last 4 quarters.
Sales by quarter
Sales by quarter
Quarter toAmount
September 2024$197m
December 2024$213m
March 2025$1.2bn
June 2025$179m
September 2025$211m
December 2025$165m
March 2026$273m
June 2026$361m
Profit by quarter
Profit by quarter
Quarter toAmount
September 2024-$107m
December 2024-$66m
March 2025$867m
June 2025-$65m
September 2025$16m
December 2025-$135m
March 2026-$3m
June 2026$83m

From the company's quarterly reports to the SEC.

Dates

Next results (estimated)
n/a
Last annual report (10-K)
19 February 2026
Next quarterly (estimated, 10-Q)
29 October 2026

Who owns it

4 long-term investors we follow own it, up from 3 last quarter. 382 funds in all.

Jun '25
Dec '25
Jun '26
Largest holders overall

From 13F filings for the quarter ended 30 June 2026.

Big holders and activists

9 investors own more than 5%.

From Schedule 13D and 13G filings: anyone owning more than 5% must file one.

What insiders did

No insider bought shares on the open market in the last 12 months. 13 sold $58m, $58m of it under preset trading plans.

  • STEELE GLENN JR MD PHD
    Director
    Sold
    under a preset trading plan
    Date
    30 September 2026
    Shares
    12,000
    Price
    $65.16
    Value
    $781,920
  • SCHMERTZLER MICHAEL
    Director
    Sold
    under a preset trading plan
    Date
    17 September 2026
    Shares
    10,000
    Price
    $67.85
    Value
    $678,533
  • SCHMERTZLER MICHAEL
    Director
    Sold
    under a preset trading plan
    Date
    16 September 2026
    Shares
    10,000
    Price
    $67.12
    Value
    $671,195
  • SCHMERTZLER MICHAEL
    Director
    Sold
    under a preset trading plan
    Date
    10 September 2026
    Shares
    10,000
    Price
    $67.34
    Value
    $673,400
  • SCHMERTZLER MICHAEL
    Director
    Sold
    under a preset trading plan
    Date
    9 September 2026
    Shares
    10,000
    Price
    $67.84
    Value
    $678,403
  • SCHMERTZLER MICHAEL
    Director
    Sold
    under a preset trading plan
    Date
    27 August 2026
    Shares
    12,500
    Price
    $71.58
    Value
    $894,784
  • SCHMERTZLER MICHAEL
    Director
    Sold
    under a preset trading plan
    Date
    26 August 2026
    Shares
    12,500
    Price
    $72.94
    Value
    $911,725
  • SCHMERTZLER MICHAEL
    Director
    Sold
    under a preset trading plan
    Date
    20 August 2026
    Shares
    12,500
    Price
    $71.11
    Value
    $888,858
  • SCHMERTZLER MICHAEL
    Director
    Sold
    under a preset trading plan
    Date
    19 August 2026
    Shares
    12,500
    Price
    $73.32
    Value
    $916,554
  • Boulding Mark Elliott
    EXEC. VP AND CLO
    Sold
    under a preset trading plan
    Date
    17 August 2026
    Shares
    2,813
    Price
    $72.57
    Value
    $204,127

From Form 4 filings: insiders must report trades in their own company's shares within two days.

Warning signs in its filings

Problems the company itself reported to the SEC, in its own words.

None of the warning signs we check for were found.

We look for five warning signs: doubt it can keep going, weak checks on its own accounts, a notice that its past accounts can't be relied on, a change of auditor, and one customer bringing in a big share of sales. We don't check lawsuits, investigations or debt yet.

We checked the auditor's report, internal controls, restatement notices, auditor changes and big customers in the 10-K filed 19 Feb 2026, plus the 10-Q filed 30 Jul 2026 and 11 later 8-Ks.

A 10-K is the yearly report every US company files with the SEC. An 8-K is a short notice of a big event.

What could go wrong

  • It owes more than it owns on paper (negative equity). Often that's from borrowing to buy back shares.
  • It isn't cheap on profits: 38.7× operating profit.

Whether the price already reflects the risks is what the deep dive is for.

The deep dive

Everything above is arithmetic on public filings. The deep dive reads the last ten years of annual reports, the proxy statements, and the earnings calls, then argues the case the way Buffett, Klarman, and Hohn would, and checks every claim against the source.

  • What the business is worth, as a range, and the margin of safety at today’s price
  • Prices to start buying, buy, and buy hard
  • The three things that would make this a mistake
  • Every number footnoted to the filing it came from
Create a free account to run it

Your first deep dive is free.

What a finished deep dive looks like

Not advice. Numbers on this page come from SEC filings and are updated each night; prices are updated again after the US market closes. The five-year figures are rounded.